Analyst Upgrades: The Coca-Cola Co, Amedisys Inc, and Sunrun Inc

Analysts upwardly revised their ratings and price targets on The Coca-Cola Co (KO), Amedisys Inc (AMED), and Sunrun Inc (RUN)

by Kirra Fedyszyn

Published on Mar 10, 2016 at 9:29 AM

Analysts are weighing in on food and beverage stock The Coca-Cola Co (NYSE:KO), health care company Amedisys Inc (NASDAQ:AMED), and solar energy concern Sunrun Inc (NASDAQ:RUN). Here's a quick roundup of today's bullish brokerage notes on KO, AMED, and RUN.

  • KO is edging higher in electronic trading, thanks to a price-target increase to $51 from $47 at RBC. The Coca-Cola Co hit a one-year high of $44.83 on Wednesday, before closing at $44.81, and is now ahead 4.3% year-to-date. The stock could stand to benefit from further bullish analyst attention -- at present, 10 of 18 brokerage firms rate KO a "hold" or worse. Meanwhile, short-term option traders continue to be optimistic -- the equity's Schaeffer's put/call open interest ratio (SOIR) of 0.37 is lower than 95% of all readings taken in the past year.
  • Oppenheimer raised its price target on AMED to $45 from $40, after the company reported better-than-expected fourth-quarter earnings earlier this week. Amedisys Inc has added 34% since hitting a year-to-date low of $32.18 in early February, and closed at $42.72 on Wednesday -- above their 200-day moving average for the first time since Jan. 22. While the stock has been a strong performer of late, speculative players have shown a preference for puts over calls. Specifically, AMED's SOIR of 1.41 sits in the 86th annual percentile.
  • Deutsche Bank initiated coverage on RUN with a "buy" rating and $15 price target -- a 126% premium over the stock's Wednesday close of $6.65, and in never-before-seen territory -- citing optimism over Sunrun Inc's cost structure, valuation, and business model. As a result, the shares, which have been on the mend since an early-February drop, are set to pop 5.3% at the open. The company is due to report quarterly earnings after the market closes tonight, and though three out of four analysts call RUN a "buy" or better, it appears a fair number of traders wouldn't mind a negative reaction -- 13% of the equity's available float is currently sold short, representing nearly seven sessions' worth of trading, at RUN's typical daily volume.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Cannabis Stock Rally Cut Short after Downgrade
Aurora Cannabis did receive a price-target hike from Jefferies, though
Vaccines, China Trigger Roller Coaster Week for Stocks
Moderna's vaccine captured the attention of Wall Street
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.